The conversation discusses using RU58841 with octopirox or essential oils for hair loss treatment. The user is seeking advice on which variation to try.
Minoxidil caused water retention and gastrointestinal issues for the user, which improved after stopping the medication. The user is now using finasteride and topical minoxidil, experiencing excessive urination and concerns about systemic absorption.
People with hair loss experience emotional struggles and body dysmorphia. Treatments like minoxidil, finasteride, and dutasteride are used, but results vary and can take time.
Minoxidil 5% is no longer effective for the user, who is considering stronger minoxidil or oral options despite availability issues. Suggestions include trying minoxidil 15%, oral minoxidil, microneedling, and exploring other treatments like finasteride and dutasteride.
User started using stemoxydine with minoxidil for mild hair recession and maintenance. Stemoxydine improves hair appearance and behavior, making it fuller and shinier.
The user started using topical minoxidil daily, finasteride every other day, and ketoconazole shampoo twice a week, along with a dermaroller. They reported progress but experienced some erection difficulties, likely due to finasteride.
Stemoxydine, a hair loss treatment, is reportedly discontinued, with some users suggesting alternatives like a rebranded version with resveratrol that may enhance Minoxidil. Some users express dissatisfaction with the discontinuation and question the product's value.
A female user is seeking feedback on using topical minoxidil on eyebrows due to eyebrow loss, as oral minoxidil hasn't worked and they avoid Latisse due to potential fat loss.
A 22-year-old male using 0.5mg Dutasteride and 2.5mg oral Minoxidil daily for 5.5 months reports increased shedding and scalp itching. He also experienced acne and is concerned about whether the shedding is normal and if daily hair washing for seborrheic dermatitis is causing dryness.
The conversation is about a user struggling with hair loss despite using dutasteride, finasteride, minoxidil, and dermaneedling. The user is considering other treatments but is hesitant to use RU-58841 due to side effects and is seeking advice on alternative solutions.
A female user in her mid-20s with androgenetic alopecia and suspected telogene effluvium who has been taking Dutasteride, Spironolactone, Minoxidil, Dermarolling, Ketoconazol shampoo, and Yaz contraception for her hair loss for the past 6 months. She had a small shed during this time that she believes to be stress related.
The conversation discusses the use of pyrrolidinyl diaminopyrmidine oxide (triaminodil) compared to minoxidil for hair loss treatment. The user is considering switching from 5% minoxidil to a product containing 5% triaminodil.
Hair loss treatments, specifically 5AR inhibitors, can impact neurosteroids and sexual health. The effects of topical fin/dut on tissue-specific DHT levels are unclear.
The user has been using oral dutasteride (DUT) for 1.5 years but is experiencing hair thinning again and is considering increasing the dose or adding topical treatments like RU58841, despite concerns about side effects. Suggestions include trying oral minoxidil or waiting to see if the thinning is just a temporary shed.
The user has been using finasteride and topical minoxidil for hair loss since April 2024 but feels their condition has worsened. They are considering switching to oral minoxidil or dutasteride for better results.
The user is considering adding RU58841 to their current hair loss treatment of finasteride and minoxidil, but is concerned about potential side effects like hairline recession and shedding. Some users report positive results with RU58841, while others experience side effects such as chest pain and dizziness.
The user has been on finasteride and minoxidil since 2020 and increased dutasteride and minoxidil doses in June 2024, but still experiences hair loss. Despite trying pyrilutamide without success, opinions vary on whether the hair loss is significant, with some suggesting it might be due to lighting, angles, or a regular shedding cycle.
The user is frustrated with dermatologists who dismiss Minoxidil and finasteride as unsafe, instead recommending mustard oil, PRP, zinc supplements, and hair products. The user feels these suggestions are ineffective and is considering starting Minoxidil and finasteride despite the dermatologists' advice.
The conversation is about a person's slow progress in treating hair loss using finasteride, microneedling, testosterone replacement therapy, dutasteride, RU58841, and minoxidil. They experienced a significant hair shed after adding dutasteride.
Hair regrowth progress after two months using oral finasteride, oral minoxidil, biotin, and vitamins. Significant improvement with new hair growth and reduced shedding.
The user plans to start hair loss treatment with minoxidil, finasteride, and microneedling, considering oral minoxidil to avoid affecting their cat. They are concerned about potential shedding and the impact of vaping on hair loss.
The user is considering stopping topical minoxidil due to lack of improvement in hair growth and is exploring alternatives like oral minoxidil, topical finasteride, and tretinoin. They are hesitant about oral finasteride and dutasteride, and are open to trying oral minoxidil if available, despite concerns about potential heart-related side effects.
The user has been using finasteride 1mg for a year and minoxidil 5% for 1.6 years, with inconsistent dermarolling, and is considering switching from topical to oral minoxidil due to hair dryness. They report increased hair thickness and no side effects, with plans to consult a dermatologist about the switch.
The conversation discusses the effectiveness of anti-androgens for hair loss, with a preference for topical treatments like RU58841 over oral options due to better scalp concentration and fewer side effects. Topical finasteride at 0.1% may provide some results, especially when combined with a topical androgen receptor antagonist like RU58841.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
The user experienced significant hair shedding after long-term use of finasteride and dutasteride and is now considering trying RU58841 as a last resort. They have checked health factors and suspect stress and poor sleep may contribute to the shedding, but they are determined to try RU58841 to see if it helps with androgenetic alopecia.
OP is experiencing severe side effects from daily Minoxidil, Dutasteride, and Biotin use and is considering reducing Minoxidil to once or twice a week. A response advised seeing a doctor due to heart-related issues.